Oral administration of carvacrol/β-cyclodextrin complex protects against 6-hydroxydopamine-induced dopaminergic denervation

Carvacrol (CARV) presents valuable biological properties such as anti-inflammatory and antioxidant activities. However, pharmacological uses of CARV are largely limited due to disadvantages related to solubility, bioavailability, preparation and storage processes. The complexation of monoterpenes wi...

Full description

Autores:
Tiefensee Ribeiro, Camila
Gasparotto, Juciano
Lintzmaier Petiz, Lyvia
Ozorio Brum, Pedro
Oppermann Peixoto, Daniel
Kunzler, Alice
Tais da Rosa Silva, Helen
Calixto Bortolin, Rafael
Farina Almeida, Roberto
Quintans-Junior, Lucindo José
Antunes Araújo, Adriano
Fonseca Moreira, José Claudio
Pens Gelain, Daniel
Tipo de recurso:
http://purl.org/coar/resource_type/c_816b
Fecha de publicación:
2019
Institución:
Corporación Universidad de la Costa
Repositorio:
REDICUC - Repositorio CUC
Idioma:
eng
OAI Identifier:
oai:repositorio.cuc.edu.co:11323/2993
Acceso en línea:
https://hdl.handle.net/11323/2993
https://repositorio.cuc.edu.co/
Palabra clave:
Carvacrol
β-cyclodextrin
6-hydroxydopamine
Parkinson’s disease
Rights
openAccess
License
Atribución – No comercial – Compartir igual
Description
Summary:Carvacrol (CARV) presents valuable biological properties such as anti-inflammatory and antioxidant activities. However, pharmacological uses of CARV are largely limited due to disadvantages related to solubility, bioavailability, preparation and storage processes. The complexation of monoterpenes with β-cyclodextrin (β-CD) increases their stability, solubility and oral bioavailability. Here, the protective effect of oral treatment with CARV/β-CD complex (25 μg/kg/day) against dopaminergic (DA) denervation induced by unilateral intranigral injection of 6-hydroxydopamine (6-OHDA - 10 μg per rat) was analyzed, in order to evaluate a putative application in the development of neuroprotective therapies for Parkinson's disease (PD). Pretreatment with CARV/β-CD for 15 days prevented the loss of DA neurons induced by 6-OHDA in adult Wistar rats. This effect may occur through CARV anti-inflammatory and antioxidant properties, as the pretreatment with CARV/β-CD inhibited the release of IL-1β and TNF-α; besides, CARV prevented the increase of mitochondrial superoxide production induced by 6-OHDA in cultured SH-SY5Y cells. Importantly, hepatotoxicity or alterations in blood cell profile were not observed with oral administration of CARV/β-CD. Therefore, this study showed a potential pharmacological application of CARV/β-CD in PD using a non-invasive route of drug delivery, i.e., oral administration.